Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bertrand

Showing results (601-610 of 606) with videos related to

Pageof 61
Sort By:
You have reached the last page of results.This site can display upto 606 results.
Nature Cancer|April 15, 2022
Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenomeBrian J Golbourn, Matthew E Halbert, Katharine Halligan, et al.
Nature Cancer|June 23, 2022
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenomeBrian J Golbourn, Matthew E Halbert, Katharine Halligan, et al.
Cell Reports|December 19, 2023
An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline gliomaStephanie M Casillo, Taylor A Gatesman, Akanksha Chilukuri, et al.
Oncologie (Paris, France)|July 21, 2015
Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (<i>Observatoire dédié au Cancer Bretagne / Pays de la Loire</i>)J P Metges, M A Lebot, R Faroux, et al.
Nature|December 21, 2017
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profilingStephen C Mack, Kristian W Pajtler, Lukas Chavez, et al.
Nature|February 21, 2014
Epigenomic alterations define lethal CIMP-positive ependymomas of infancyS C Mack, H Witt, R M Piro, et al.
Pageof 61

Showing results (601-610 of 606) with videos related to

Sort By:
Pageof 61
You have reached the last page of results.This site can display upto 606 results.
Nature Cancer|April 15, 2022
Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenomeBrian J Golbourn, Matthew E Halbert, Katharine Halligan, et al.
Nature Cancer|June 23, 2022
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenomeBrian J Golbourn, Matthew E Halbert, Katharine Halligan, et al.
Cell Reports|December 19, 2023
An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline gliomaStephanie M Casillo, Taylor A Gatesman, Akanksha Chilukuri, et al.
Oncologie (Paris, France)|July 21, 2015
Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (<i>Observatoire dédié au Cancer Bretagne / Pays de la Loire</i>)J P Metges, M A Lebot, R Faroux, et al.
Nature|December 21, 2017
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profilingStephen C Mack, Kristian W Pajtler, Lukas Chavez, et al.
Nature|February 21, 2014
Epigenomic alterations define lethal CIMP-positive ependymomas of infancyS C Mack, H Witt, R M Piro, et al.
Pageof 61